GlassScriptPhysician profile
Cecily D Havert
NPI 1700998309
$2,559.67
in general payments reported to CMS, 2019-2025
22 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $120 · 2021: $45.39 · 2022: $198 · 2023: $473 · 2024: $816 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $492.48 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $284.55 | 2022-2025 | |
| Lilly USA, LLC | $263.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $230.57 | 2021-2025 | |
| Gilead Sciences, INC. | $185.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $85.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $63.89 | 2020-2023 | |
| Astellas Pharma US INC | $47.81 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $42.94 | 2024 | |
| Glaxosmithkline, LLC. | $30.97 | 2019 | |
| Ucb, INC. | $26.44 | 2022 | |
| Merck Sharp & Dohme LLC | $26.31 | 2019-2020 | |
| Becton, Dickinson and Company | $24.18 | 2025 | Bd Max System, Bd Max Instrument |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $22.27 | 2022 | |
| Bausch Health US, LLC | $21.18 | 2023 | Aplenzin |
| Medtronic, INC. | $16.51 | 2024 | Intellis Adaptivestim |
| Adlon Therapeutics L.P. | $16.43 | 2020 | |
| Quidel Corporation | $12.90 | 2019 | |
| Amarin Pharma, INC. | $12.09 | 2020 | |
| Shield Therapeutics INC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecily Havert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.